Latest news and press releases about NeuroPace, Inc. (NPCE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
Price
| Price | $14.10 |
| Market Cap | $481M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 39.18 |
| EV / EBITDA | -43.63 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -119.68% |
| Return on Invested Capital | -18.43% |
| Return on Assets | -19.71% |
| Gross Margin | 79.63% |
| Operating Margin | -15.26% |
| Net Margin | -19.34% |
Explore sector: Healthcare · Medical - Devices
More sections of NPCE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks